Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sugarman

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Journal of Magnetic Resonance Imaging : JMRI|January 1, 1996
Report from efficacy subgroup MR methodology workshopW C Black, C A Beam, J Camaratta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factorJ L Abbruzzese, T Madden, S M Sugarman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinomaR Pazdur, Y Lassere, V Rhodes, et al.
Clinical Breast Cancer|December 15, 2010
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancerPamela Drullinsky, Steven M Sugarman, Monica N Fornier, et al.
Breast Cancer Research and Treatment|June 17, 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II studyL M Smyth, N M Iyengar, M F Chen, et al.
Pediatric Emergency Care|April 12, 2022
Understanding Bilateral Skull Fractures in Infancy: A Retrospective Multicenter Case ReviewMandy A O'Hara, Thomas J Valvano, Marisha Kashyap, et al.
Clinical Breast Cancer|October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerNeil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of Magnetic Resonance Imaging : JMRI|January 1, 1996
Report from efficacy subgroup MR methodology workshopW C Black, C A Beam, J Camaratta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factorJ L Abbruzzese, T Madden, S M Sugarman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinomaR Pazdur, Y Lassere, V Rhodes, et al.
Clinical Breast Cancer|December 15, 2010
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancerPamela Drullinsky, Steven M Sugarman, Monica N Fornier, et al.
Breast Cancer Research and Treatment|June 17, 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II studyL M Smyth, N M Iyengar, M F Chen, et al.
Pediatric Emergency Care|April 12, 2022
Understanding Bilateral Skull Fractures in Infancy: A Retrospective Multicenter Case ReviewMandy A O'Hara, Thomas J Valvano, Marisha Kashyap, et al.
Clinical Breast Cancer|October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerNeil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.
Pageof 5